Swedish Orphan Biovitrum AB · OMXSTO:SOBI
Swedish Orphan Biovitrum AB — Merger or Acquisition (November 2009)
28 slides from Swedish Orphan Biovitrum AB's merger presentation, Nov 5, 2009
Slide 1: Press conference
Press conference November 5, 2009 1
Slide 2: Disclaimer
DISCLAIMER IMPORTANT NOTICE: The information in this presentation is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore. The information in this presentation shall not constit
Slide 3: Table of contents
Table of contents 1. Combination rationale and overview 2. Biovitrum 3. Swedish Orphan International 4. The New Group 3
Slide 4: So-Bi - Strong industrial logic - set for growth
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Swedish Orphan International and Biovitrum (“So-Bi”) - Strong industrial logic – set for growth and cash flow generation 1. Shared mission and business philosophy – Addressing the need of patients with rare disea
Slide 5: Shared mission and why rare diseases
Combination Swedish Orphan rationale and Biovitrum The New Group International overview 1. Shared mission and business philosophy Shared mission Why rare diseases? 350 327 312 297 Total number of orphan drugs approved 300 275 257 244 250 232 218 200 150 Mission to develop and make available orphan d
Slide 6: Complementary capabilities
Combination Swedish Orphan rationale and Biovitrum The New Group International overview 2. Complementary capabilities Sales & Product Sales & Product Marketing development Marketing development Sales & Product Marketing development Manufac- Business Business Manufacturing turing development developm
Slide 7: Strong platform for growth in existing portfolio
Combination Swedish Orphan rationale and Biovitrum The New Group International overview 3. Strong platform for growth in existing portfolio Attractive growth outlook Financial targets • Sales growth – 2010-2011: 13-15% p.a. Further potential in additional business development during 2010-2015 – 2012
Slide 8: Transaction terms and time table
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Transaction terms and time table Transaction terms Preliminary time table • Upfront price of SEK 3.5 billion1 November – Additional earn out payment up to SEK 425 million based 5 Announcement on success in Multif
Slide 9: Table of contents
Table of contents 1. Combination rationale and overview 2. Biovitrum 3. Swedish Orphan International 4. The New Group 9
Slide 10: Pharmaceutical company focusing on rare diseases
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Pharmaceutical company focusing on rare diseases • Founded in 2001 with long heritage from protein drugs • About 400 employees. The majority in Sweden/Nordic countries • 8 marketed products • 1 development projec
Slide 11: Transformation towards specialist pharmaceuticals
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Transformation towards specialist pharmaceuticals 2007-2009 – preparing for growth Development of revenues • Focus on rare diseases 100% • R&D restructuring 80% As % of total sales 60% • Strengthening the commerc
Slide 12: Table of contents
Table of contents 1. Combination rationale and overview 2. Biovitrum 3. Swedish Orphan International 4. The New Group 12
Slide 13: A pioneer and market leader serving rare disease patients
Combination Swedish rationale and Biovitrum Orphan The New Group overview International A pioneer and market leader serving rare disease patients... • Founded in 1988 • 130 employees of which ~90 in local market subsidiaries/offices • Broad portfolio of approximately 50 orphan drugs/niche specialty
Slide 14: ...with a unique position
Combination Swedish rationale and Biovitrum Orphan The New Group overview International …with a unique position • In-depth orphan drug expertise – Diversified portfolio and established networks across a broad range of therapeutic areas – Successful track-record in optimizing returns of smaller niche
Slide 15: Pan-European presence
Combination Swedish rationale and Biovitrum Orphan The New Group overview International Pan-European presence Norway Sweden • European presence Employees: 10 Employees: 12 through 11 subsidiaries and 6 branch offices Denmark and Iceland Finland – Covering all Europe Employees: 9 – Sales in over 50 E
Slide 16: Successful contract portfolio expansion with new additions
Combination Swedish rationale and Biovitrum Orphan The New Group overview International Successful contract portfolio expansion with new additions Equasym 60 Buronil Promixin Fomepizole Fosrenol Yondelis 50 Atamir Proleukin Ammonaps Voraxaze CroTAb Tracleer DigiTAb Viread Ferriprox Ammonul Number of
Slide 17: Swedish Orphan profit and loss account
Combination Swedish rationale and Biovitrum Orphan The New Group overview International Swedish Orphan profit and loss account P&L (2006/07-2009/10e) Sales per product (2009/10e) SEK million 2006/07 2007/08 2008/09 2009/10e Reported sales 684 765 694 800-820 Growth 12% -9% ~17% COGS Ta -375 bort -37
Slide 18: Strong financial performance
Combination Swedish rationale and Biovitrum Orphan The New Group overview International Strong financial performance 1,000 250 2004/05 – 2008/09 CAGR: • Net Sales: 18% 800-820 800 765 200 • EBIT: 45% 684 694 Sales (SEK million) 650 EBIT (SEK million) 600 559 150 465 476 400 357 100 315 252 200 50 0
Slide 19: Table of contents
Table of contents 1. Combination rationale and overview 2. Biovitrum 3. Swedish Orphan International 4. The New Group 19
Slide 20: The combination of Swedish Orphan and Biovitrum
Combination Swedish Orphan rationale and Biovitrum The New Group International overview The combination of Swedish Orphan and Biovitrum 1. Shared mission and business philosophy – Addressing the need of patients with rare diseases – Diversified portfolio of orphan drugs and niche specialty pharmaceu
Slide 21: Complementary capabilities
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Complementary capabilities Sales & Product Sales & Product Marketing development Marketing development Sales & Product Marketing development Manufac- Business Business Manufacturing turing development development
Slide 22: Strong commercial presence
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Strong commercial presence Local representation and branch offices Footprint through contract organization and distribution partner Distribution partner in the Middle East Local representation Branch office Distr
Slide 23: Key products addressing the needs of patients with rare diseases
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Key products addressing the needs of patients with rare diseases Share of total Product Therapy Disease indication Commercial rights sales (2009e) Hematology Hemophilia A Nordic Inflammatory Rheumatoid arthritis
Slide 24: ...plus another 50 commercial products in its portfolio
Combination Swedish Orphan rationale and Biovitrum The New Group International overview …plus another 50 commercial products in its portfolio Actiq Caphosol Euphylong Mezavant Syntocinon Aloxi Carnitor Ferriprox Mimpara Tracleer AmBisome Collatamp Fomepizole Novastan Truvada Ammonul Cyanokit Fosreno
Slide 25: Emerging late stage clinical development pipeline
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Emerging late stage clinical development pipeline Phase Phase Indication Project Partner Phase I Reg. II III 2nd line to rIFNs Multiferon® ** Hemophilia B rFactor IX Fc Fat malabsorption in preterm infants Kiobri
Slide 26: The New Group profit and loss account
Combination Swedish Orphan rationale and Biovitrum The New Group International overview The New Group profit and loss account Pro forma P&L (2008 and 2009e) Sales per product (2009e) Biovitrum Swedish Orphan New Group SEK million 2008 2009e 2008 2009e 2008 2009e Sales 1,141 1,210-1,230 718 770-780 1
Slide 27: Ownership structure
Combination Swedish Orphan rationale and Biovitrum The New Group International overview Ownership structure Biovitrum pre combination Swedish Orphan pre combination Investor Management 23% 16% Others 40% IGC 42% MPM 19% Priveq 42% Alta Amgen 5% Orkla 7% 5% The New Group Others Investor 29% 41% Swedi
Slide 28: So-Bi - Strong industrial logic
Combination Swedish Orphan rationale and Biovitrum The New Group International overview So-Bi – Strong industrial logic 1. Shared mission and business philosophy Product Sales & Marketing development 2. Complementary capabilities 3. Strong platform for profitable growth Business Manufacturing develo
Swedish Orphan Biovitrum — Merger or Acquisition (November 2009) on 6ix